2026 Q2 -tulosraportti
15 päivää sitten
‧28 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 890 | - | - | ||
| 609 | - | - | ||
| 150 | - | - | ||
| 100 | - | - | ||
| 100 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 21.8. | ||
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·17 t sitten · MuokattuOK, now information arrived about more of Egetis' activities for medical market information and penetration. More of this is needed!- ·1 päivä sittenProbably good for increased visibility with participation in yet another investor conference, but I hope for focus on visibility in medical conferences for increased awareness of the disease itself. I imagine that the focus will shift to the number of klinter after September 28. How large is the customer base and how large a share can Egetis penetrate and capture?Yes, perhaps. But which growth curve is realistic? Revenue/individual 100kUSD/person per year. Monopoly for how long?
·28.8.I allow myself to repeat this post so that any new shareholders are not scared by Nordnet and Pareto not correcting a totally erroneous price target: Here is the story of the erroneous price target of 1.6, which is still displayed on Nordnet's page: The low share price is probably due to continued after-effects of Pareto's catastrophic erroneous analysis at the end of November, where the analyst believed that there were already other products on the market that Egetis would have to compete with and lowered the price target to 1.60. A couple of days later, a price target came from Redeye, which was apparently around 13. Pareto's erroneous analytical basis, which many others fortunately objected to - but which Pareto has not corrected and acted upon - and which Nordnet unfortunately continues to propagate as "lowest price target" instead of removing it when it was demonstrably based on an error - or asking Pareto to retract their erroneous analysis. Incidentally, the situation was so abnormal - that rarely seen reactions were highly appropriate. I have never seen another analysis firm directly attack Pareto and their analytical basis, as we fortunately saw some do in November. It was highly necessary and commendably quick - and completely unprecedented. If you have forgotten the matter, look at the posts below at the end of November. Here is an excerpt from Stiefel's correction, which shows Pareto's misconception - but see more below in November. "Pareto lowered its recommendation for the stock on Wednesday to sell from hold with a target price reduction to 1:60 kronor from a previous 6 kronor. In (the erroneous) analysis, Pareto wrote that an American price for Emcitate of 0.1 million dollars per year seems extremely high without any proven neurocognitive effect. Especially considering that there is a much cheaper alternative treatment (PTU+LT4) for thyrotoxicosis, a condition with an increased amount of thyroid hormone in the blood regardless of cause."
I was wrong about this, the answer from Nordnet: Thank you for your message. That's a good question. Nordnet takes no position whatsoever regarding target prices and assumptions. Analysts make assumptions about factors such as demand, growth, and competition to estimate what a stock might be worth and what its price might be in the future, in this case 12 months from publication. Target prices are based on the circumstances at the time of publication. Please note that target prices can be up to 90 days old. If an analyst has published several target prices in the last 90 days, the newest one is included in the data. Make sure to make your own assessment and do not rely solely on analysts' assessments. If you have questions regarding target prices, you should contact the institution that monitors and sets them directly. It is therefore not Nordnet's analysts who set target prices. We do not engage in investment advice and remain completely impartial regarding the development of specific securities. I wish you a nice day.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
15 päivää sitten
‧28 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17 t sitten · MuokattuOK, now information arrived about more of Egetis' activities for medical market information and penetration. More of this is needed!
- ·1 päivä sittenProbably good for increased visibility with participation in yet another investor conference, but I hope for focus on visibility in medical conferences for increased awareness of the disease itself. I imagine that the focus will shift to the number of klinter after September 28. How large is the customer base and how large a share can Egetis penetrate and capture?Yes, perhaps. But which growth curve is realistic? Revenue/individual 100kUSD/person per year. Monopoly for how long?
- ·28.8.I allow myself to repeat this post so that any new shareholders are not scared by Nordnet and Pareto not correcting a totally erroneous price target: Here is the story of the erroneous price target of 1.6, which is still displayed on Nordnet's page: The low share price is probably due to continued after-effects of Pareto's catastrophic erroneous analysis at the end of November, where the analyst believed that there were already other products on the market that Egetis would have to compete with and lowered the price target to 1.60. A couple of days later, a price target came from Redeye, which was apparently around 13. Pareto's erroneous analytical basis, which many others fortunately objected to - but which Pareto has not corrected and acted upon - and which Nordnet unfortunately continues to propagate as "lowest price target" instead of removing it when it was demonstrably based on an error - or asking Pareto to retract their erroneous analysis. Incidentally, the situation was so abnormal - that rarely seen reactions were highly appropriate. I have never seen another analysis firm directly attack Pareto and their analytical basis, as we fortunately saw some do in November. It was highly necessary and commendably quick - and completely unprecedented. If you have forgotten the matter, look at the posts below at the end of November. Here is an excerpt from Stiefel's correction, which shows Pareto's misconception - but see more below in November. "Pareto lowered its recommendation for the stock on Wednesday to sell from hold with a target price reduction to 1:60 kronor from a previous 6 kronor. In (the erroneous) analysis, Pareto wrote that an American price for Emcitate of 0.1 million dollars per year seems extremely high without any proven neurocognitive effect. Especially considering that there is a much cheaper alternative treatment (PTU+LT4) for thyrotoxicosis, a condition with an increased amount of thyroid hormone in the blood regardless of cause."I was wrong about this, the answer from Nordnet: Thank you for your message. That's a good question. Nordnet takes no position whatsoever regarding target prices and assumptions. Analysts make assumptions about factors such as demand, growth, and competition to estimate what a stock might be worth and what its price might be in the future, in this case 12 months from publication. Target prices are based on the circumstances at the time of publication. Please note that target prices can be up to 90 days old. If an analyst has published several target prices in the last 90 days, the newest one is included in the data. Make sure to make your own assessment and do not rely solely on analysts' assessments. If you have questions regarding target prices, you should contact the institution that monitors and sets them directly. It is therefore not Nordnet's analysts who set target prices. We do not engage in investment advice and remain completely impartial regarding the development of specific securities. I wish you a nice day.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 890 | - | - | ||
| 609 | - | - | ||
| 150 | - | - | ||
| 100 | - | - | ||
| 100 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 21.8. | ||
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
15 päivää sitten
‧28 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 21.8. | ||
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17 t sitten · MuokattuOK, now information arrived about more of Egetis' activities for medical market information and penetration. More of this is needed!
- ·1 päivä sittenProbably good for increased visibility with participation in yet another investor conference, but I hope for focus on visibility in medical conferences for increased awareness of the disease itself. I imagine that the focus will shift to the number of klinter after September 28. How large is the customer base and how large a share can Egetis penetrate and capture?Yes, perhaps. But which growth curve is realistic? Revenue/individual 100kUSD/person per year. Monopoly for how long?
- ·28.8.I allow myself to repeat this post so that any new shareholders are not scared by Nordnet and Pareto not correcting a totally erroneous price target: Here is the story of the erroneous price target of 1.6, which is still displayed on Nordnet's page: The low share price is probably due to continued after-effects of Pareto's catastrophic erroneous analysis at the end of November, where the analyst believed that there were already other products on the market that Egetis would have to compete with and lowered the price target to 1.60. A couple of days later, a price target came from Redeye, which was apparently around 13. Pareto's erroneous analytical basis, which many others fortunately objected to - but which Pareto has not corrected and acted upon - and which Nordnet unfortunately continues to propagate as "lowest price target" instead of removing it when it was demonstrably based on an error - or asking Pareto to retract their erroneous analysis. Incidentally, the situation was so abnormal - that rarely seen reactions were highly appropriate. I have never seen another analysis firm directly attack Pareto and their analytical basis, as we fortunately saw some do in November. It was highly necessary and commendably quick - and completely unprecedented. If you have forgotten the matter, look at the posts below at the end of November. Here is an excerpt from Stiefel's correction, which shows Pareto's misconception - but see more below in November. "Pareto lowered its recommendation for the stock on Wednesday to sell from hold with a target price reduction to 1:60 kronor from a previous 6 kronor. In (the erroneous) analysis, Pareto wrote that an American price for Emcitate of 0.1 million dollars per year seems extremely high without any proven neurocognitive effect. Especially considering that there is a much cheaper alternative treatment (PTU+LT4) for thyrotoxicosis, a condition with an increased amount of thyroid hormone in the blood regardless of cause."I was wrong about this, the answer from Nordnet: Thank you for your message. That's a good question. Nordnet takes no position whatsoever regarding target prices and assumptions. Analysts make assumptions about factors such as demand, growth, and competition to estimate what a stock might be worth and what its price might be in the future, in this case 12 months from publication. Target prices are based on the circumstances at the time of publication. Please note that target prices can be up to 90 days old. If an analyst has published several target prices in the last 90 days, the newest one is included in the data. Make sure to make your own assessment and do not rely solely on analysts' assessments. If you have questions regarding target prices, you should contact the institution that monitors and sets them directly. It is therefore not Nordnet's analysts who set target prices. We do not engage in investment advice and remain completely impartial regarding the development of specific securities. I wish you a nice day.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 890 | - | - | ||
| 609 | - | - | ||
| 150 | - | - | ||
| 100 | - | - | ||
| 100 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt